Market Closed -
Nasdaq
21:00:00 09/05/2024 BST
|
5-day change
|
1st Jan Change
|
7.73
USD
|
-3.38%
|
|
-9.06%
|
-1.90%
|
Fiscal Period: September |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
42.07
|
91.57
|
380.5
|
275.9
|
57.51
|
186.4
|
-
|
-
|
Enterprise Value (EV)
1 |
42.07
|
91.57
|
380.5
|
275.9
|
57.51
|
186.4
|
186.4
|
186.4
|
P/E ratio
|
-0.75
x
|
-1.07
x
|
-6.2
x
|
-3.94
x
|
-0.92
x
|
-2.4
x
|
-3.44
x
|
-9.02
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
5.16
x
|
-
|
-
|
-
|
-
|
915
x
|
15.7
x
|
2.26
x
|
EV / Revenue
|
5.16
x
|
-
|
-
|
-
|
-
|
915
x
|
15.7
x
|
2.26
x
|
EV / EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / FCF
|
-1,285,407
x
|
-
|
-
|
-4,868,083
x
|
-
|
-
|
-
|
-
|
FCF Yield
|
-0%
|
-
|
-
|
-0%
|
-
|
-
|
-
|
-
|
Price to Book
|
-3.92
x
|
-
|
71.9
x
|
29.6
x
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
1,412
|
6,359
|
8,767
|
11,307
|
13,012
|
23,298
|
-
|
-
|
Reference price
2 |
29.80
|
14.40
|
43.40
|
24.40
|
4.420
|
8.000
|
8.000
|
8.000
|
Announcement Date
|
19/12/19
|
23/12/20
|
22/12/21
|
29/12/22
|
22/12/23
|
-
|
-
|
-
|
Fiscal Period: September |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
8.146
|
-
|
-
|
-
|
-
|
0.2037
|
11.85
|
82.51
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-36.3
|
-36.84
|
-51.73
|
-63.07
|
-53.13
|
-67.51
|
-57.13
|
-9.752
|
Operating Margin
|
-445.6%
|
-
|
-
|
-
|
-
|
-33,140.9%
|
-481.93%
|
-11.82%
|
Earnings before Tax (EBT)
1 |
-37.93
|
-38.51
|
-53.16
|
-66.05
|
-58.98
|
-71.85
|
-62
|
-13.08
|
Net income
1 |
-36.04
|
-48.87
|
-53.16
|
-66.05
|
-58.98
|
-71.99
|
-62
|
-13
|
Net margin
|
-442.42%
|
-
|
-
|
-
|
-
|
-35,337.65%
|
-522.99%
|
-15.76%
|
EPS
2 |
-39.60
|
-13.40
|
-7.000
|
-6.200
|
-4.800
|
-3.337
|
-2.328
|
-0.8867
|
Free Cash Flow
|
-32.73
|
-
|
-
|
-56.67
|
-
|
-
|
-
|
-
|
FCF margin
|
-401.75%
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
19/12/19
|
23/12/20
|
22/12/21
|
29/12/22
|
22/12/23
|
-
|
-
|
-
|
Fiscal Period: September |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
0.2037
|
-
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-13.44
|
-13.15
|
-18.91
|
-17.02
|
-13.99
|
-15.69
|
-6.838
|
-18.14
|
-12.46
|
-10.32
|
-16.92
|
-20.99
|
-19.23
|
-14
|
-14
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-9,441.94%
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-13.4
|
-14.46
|
-19.7
|
-17.54
|
-14.34
|
-18.66
|
-6.651
|
-20.68
|
-12.99
|
-11.18
|
-18.35
|
-22.13
|
-20.13
|
-16.5
|
-16.5
|
Net income
1 |
-13.4
|
-14.46
|
-19.7
|
-17.54
|
-14.34
|
-18.66
|
-6.654
|
-20.68
|
-12.99
|
-11.18
|
-18.11
|
-22.14
|
-20.52
|
-16.5
|
-16.5
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-10,072%
|
-
|
-
|
EPS
2 |
-1.600
|
-1.600
|
-1.800
|
-1.600
|
-1.200
|
-1.600
|
-0.6000
|
-1.600
|
-1.000
|
-0.8000
|
-0.9050
|
-0.8550
|
-0.8917
|
-0.8000
|
-0.8000
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
22/12/21
|
14/02/22
|
13/05/22
|
10/08/22
|
29/12/22
|
14/02/23
|
15/05/23
|
14/08/23
|
22/12/23
|
14/02/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: September |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-32.7
|
-
|
-
|
-56.7
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-7.600
|
-
|
0.6000
|
0.8200
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
|
0.44
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex / Sales
|
5.37%
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
19/12/19
|
23/12/20
|
22/12/21
|
29/12/22
|
22/12/23
|
-
|
-
|
-
|
Average target price
39.86
USD Spread / Average Target +398.21% Consensus |
1st Jan change
|
Capi.
|
---|
| -1.90% | 186M | | +23.37% | 46.71B | | +48.83% | 41.8B | | -0.94% | 41.52B | | -5.86% | 29.55B | | +11.29% | 25.78B | | -20.92% | 19.26B | | +3.20% | 12.14B | | -2.67% | 12.08B | | +30.23% | 11.98B |
Other Biotechnology & Medical Research
|